IS7726A - Pyrazólólpyridín og aðferðir til þess að búa þau til og nota - Google Patents

Pyrazólólpyridín og aðferðir til þess að búa þau til og nota

Info

Publication number
IS7726A
IS7726A IS7726A IS7726A IS7726A IS 7726 A IS7726 A IS 7726A IS 7726 A IS7726 A IS 7726A IS 7726 A IS7726 A IS 7726A IS 7726 A IS7726 A IS 7726A
Authority
IS
Iceland
Prior art keywords
pyrazolol
pyridine
preparation
methods
pyrazolol pyridine
Prior art date
Application number
IS7726A
Other languages
English (en)
Inventor
Lee Wen-Cherng
Lyne Paul
Singh Juswinder
Beth Carter Mary
Chuaqui Claudio
Somerville
Boriack-Sjodin Paula
Sun Lihong
Zheng Zhongli
Original Assignee
Biogen Idec Ma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma, Inc. filed Critical Biogen Idec Ma, Inc.
Publication of IS7726A publication Critical patent/IS7726A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS7726A 2002-09-06 2005-03-04 Pyrazólólpyridín og aðferðir til þess að búa þau til og nota IS7726A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40881102P 2002-09-06 2002-09-06
PCT/US2003/027722 WO2004022054A1 (en) 2002-09-06 2003-09-05 Pyrazolopyridines and methods of making and using the same

Publications (1)

Publication Number Publication Date
IS7726A true IS7726A (is) 2005-03-04

Family

ID=31978684

Family Applications (2)

Application Number Title Priority Date Filing Date
IS7726A IS7726A (is) 2002-09-06 2005-03-04 Pyrazólólpyridín og aðferðir til þess að búa þau til og nota
IS7725A IS7725A (is) 2002-09-06 2005-03-04 Imidazólópyridín og aðferðir við framleiðslu og notkun þeirra

Family Applications After (1)

Application Number Title Priority Date Filing Date
IS7725A IS7725A (is) 2002-09-06 2005-03-04 Imidazólópyridín og aðferðir við framleiðslu og notkun þeirra

Country Status (20)

Country Link
US (1) US7691865B2 (is)
EP (1) EP1551398A4 (is)
JP (1) JP2006502165A (is)
KR (1) KR20050057235A (is)
CN (1) CN1694698A (is)
AR (1) AR041207A1 (is)
AU (1) AU2003268447B2 (is)
BR (1) BR0314053A (is)
CA (1) CA2497970A1 (is)
EA (1) EA009441B1 (is)
GE (1) GEP20074125B (is)
IS (2) IS7726A (is)
MX (1) MXPA05002443A (is)
NO (1) NO20051503D0 (is)
NZ (1) NZ539069A (is)
PL (1) PL375699A1 (is)
RS (1) RS20050200A (is)
UA (1) UA80295C2 (is)
WO (1) WO2004022054A1 (is)
ZA (1) ZA200501856B (is)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
JP4931589B2 (ja) * 2004-07-02 2012-05-16 正明 松岡 ＴＧＦβ２を標的としたアルツハイマー病治療薬のスクリーニング法
AU2005295734A1 (en) * 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
JP2009507032A (ja) 2005-09-02 2009-02-19 アボット・ラボラトリーズ 新規なイミダゾ系複素環
EP1873157A1 (en) * 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
HUE035575T2 (en) 2006-10-03 2018-05-28 Genzyme Corp Use of TGF-beta antagonists to treat children at risk of developing bronchopulmonary dysplasia
EP2203453A1 (en) * 2007-09-20 2010-07-07 Wyeth a Corporation of the State of Delaware Pyrazolo[5, 1-c] [1,2,4]triazines, methods for preparation and use thereof
SG188852A1 (en) * 2008-03-14 2013-04-30 Otsuka Pharma Co Ltd Mmp-2 and/or mmp-9 inhibitor
CN101544634B (zh) * 2008-03-27 2011-08-10 天津药物研究院 2-苯基-3-取代吡唑并[1,5-a]吡啶类衍生物及其制备方法和用途
EP2402344A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazole fused bicyclic compounds
EP2402335A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
CA2853484C (en) 2011-10-26 2018-08-21 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
JP6433974B2 (ja) 2013-03-14 2018-12-05 トレロ ファーマシューティカルズ， インコーポレイテッド Ｊａｋ２およびａｌｋ２阻害剤およびその使用方法
PL3035936T3 (pl) 2013-08-23 2019-08-30 Neupharma, Inc. Pewne jednostki chemiczne, kompozycje i sposoby
AU2014372638A1 (en) 2013-12-23 2016-06-16 Norgine B.V. Compounds useful as CCR9 modulators
US10342795B2 (en) * 2014-03-27 2019-07-09 Janssen Pharmaceutica Nv Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors
CA3033370A1 (en) * 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
CA3103995A1 (en) 2018-07-26 2020-01-30 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
CN114126620B (zh) * 2019-05-13 2024-12-31 传达治疗有限公司 Fgfr抑制剂和其使用方法
CA3164037A1 (en) 2020-01-08 2021-07-15 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
CN112707902B (zh) * 2020-03-23 2022-04-15 杭州阿诺生物医药科技有限公司 TGF-β受体抑制剂
CN114380818A (zh) * 2020-10-16 2022-04-22 四川科伦博泰生物医药股份有限公司 吡唑并吡啶类化合物，及其药物组合物、制备方法和用途
WO2024258967A1 (en) 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940486A (en) 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4302464A (en) 1980-10-16 1981-11-24 Pfizer Inc. Imidazolylpyridine therapeutic agents
US4686231A (en) 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
JP2753659B2 (ja) * 1990-09-03 1998-05-20 株式会社大塚製薬工場 ピラゾール誘導体
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
MX9300141A (es) 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5670527A (en) 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US5593991A (en) 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5559137A (en) 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
GB9423460D0 (en) 1994-11-21 1995-01-11 Merck Sharp & Dohme Therapeutic agents
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
US5739143A (en) 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
US5658903A (en) 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US6369068B1 (en) 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
WO1997001575A1 (fr) 1995-06-29 1997-01-16 Fujisawa Pharmaceutical Co., Ltd. Substance wf16616, procede de production et utilisation
US5792778A (en) 1995-08-10 1998-08-11 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5837719A (en) 1995-08-10 1998-11-17 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
US6083949A (en) 1995-10-06 2000-07-04 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
ZA9610687B (en) 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
IL125223A0 (en) 1996-01-11 1999-03-12 Smithkline Beecham Corp Novel substituted imidazole compounds
US6046208A (en) 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
ZA97175B (en) 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
US6136828A (en) 1996-02-01 2000-10-24 Smithkline Beecham Corporation Endothelin receptor antagonists
WO1997032583A1 (en) 1996-03-08 1997-09-12 Smithkline Beecham Corporation Use of csaidtm compounds as inhibitors of angiogenesis
US6096748A (en) 1996-03-13 2000-08-01 Smithkline Beecham Corporation Pyrimidine compounds useful in treating cytokine mediated diseases
WO1997035855A1 (en) 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries
US6096739A (en) 1996-03-25 2000-08-01 Smithkline Beecham Corporation Treatment for CNS injuries
US5854265A (en) 1996-04-03 1998-12-29 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5872136A (en) 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
US5880140A (en) 1996-04-03 1999-03-09 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5939557A (en) 1996-04-03 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6080870A (en) 1996-04-03 2000-06-27 Merck & Co., Inc. Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5883105A (en) 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP3418624B2 (ja) 1996-06-10 2003-06-23 メルク エンド カンパニー インコーポレーテッド サイトカイン阻害活性を有する置換イミダゾール類
US5854264A (en) 1996-07-24 1998-12-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ES2215242T3 (es) 1996-11-19 2004-10-01 Amgen Inc. Agentes antiinflamatorios de pirrol condensado sustituido con arilo y heteroarilo.
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US5939439A (en) 1996-12-30 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
BR9808998A (pt) 1997-04-24 2000-08-08 Ortho Mcneil Pharm Inc Imidazóis substituìdos úteis no tratamento de doenças inflamatórias
PL336990A1 (en) 1997-05-22 2000-07-31 Searle & Co 3(5)-heteroaryl group substituted pyrazoles as inhibitors of kinase p 38
JP2002502380A (ja) 1997-05-22 2002-01-22 ジー．ディー．サール アンド カンパニー ｐ３８キナーゼ阻害剤としてのピラゾール誘導体
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6087496A (en) 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
DE69835518T2 (de) 1997-06-12 2007-08-09 Aventis Pharma Ltd., West Malling Imidazolyl-cyclische acetale
EP1023066A4 (en) 1997-06-13 2001-05-23 Smithkline Beecham Corp NEW PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUND
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
AU8757098A (en) 1997-06-30 1999-02-10 Ortho-Mcneil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
CA2314980A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
ATE266399T1 (de) 1998-08-20 2004-05-15 Smithkline Beecham Corp Neue substituierte triazolverbindungen
EP1126852B1 (en) 1998-11-04 2004-01-21 SmithKline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
US6288089B1 (en) 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
ATE301116T1 (de) 1998-12-25 2005-08-15 Teikoku Hormone Mfg Co Ltd Aminopyrazol derivate
CA2368630A1 (en) 1999-04-02 2000-10-12 Ruth R. Wexler Aryl sulfonyls as factor xa inhibitors
WO2000061576A1 (en) 1999-04-09 2000-10-19 Smithkline Beecham Corporation Triarylimidazoles
CO5170501A1 (es) 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
WO2000075131A1 (fr) 1999-06-03 2000-12-14 Teikoku Hormone Mfg. Co., Ltd. Composes a base de pyrazole substitue
ES2260033T3 (es) 1999-07-02 2006-11-01 Stuart A. Lipton Uso de los inhibidores p38 mapk en efermadades oftalmicas.
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
US20030109428A1 (en) 1999-12-01 2003-06-12 John Bertin Novel molecules of the card-related protein family and uses thereof
ATE299881T1 (de) 1999-12-21 2005-08-15 Sugen Inc 4-substituierte 7-aza-indolin-2-one und ihre anwendung als protein kinase inhibitoren
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
US7235658B2 (en) 2000-03-06 2007-06-26 Smithkline Beecham P.L.C. Imidazol derivatives as Raf kinase inhibitors
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
JP4722318B2 (ja) * 2000-06-05 2011-07-13 ローム株式会社 チップ抵抗器
GB0011092D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (III)
EP1289523A1 (en) 2000-06-01 2003-03-12 Merck & Co., Inc. Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
EP1296977A1 (en) 2000-06-23 2003-04-02 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
ATE327992T1 (de) 2000-09-15 2006-06-15 Vertex Pharma Pyrazolverbindungen als protein-kinasehemmer
KR20030030027A (ko) 2000-09-21 2003-04-16 스미스클라인비이참피이엘시이 Ｒａｆ 키나제 저해제인 이미다졸 유도체
US7041686B2 (en) 2000-10-18 2006-05-09 Scott Beers Substituted imidazoles useful in the treatment of inflammatory diseases
US6630325B1 (en) 2000-10-19 2003-10-07 Maine Medical Center Research Institute Compositions, methods and kits relating to remodel
US6603005B2 (en) 2000-11-15 2003-08-05 Aventis Pharma S.A. Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them
GB0027987D0 (en) 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
US20040039198A1 (en) 2000-11-16 2004-02-26 Bender Paul E. Compounds
JP4217480B2 (ja) 2000-11-20 2009-02-04 スミスクライン・ビーチャム・コーポレイション 新規化合物
CZ20031777A3 (cs) * 2000-12-28 2003-10-15 Ono Pharmaceutical Co., Ltd. Triheterocyklické sloučeniny a léčivo na jejich bázi
GB0102668D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
US20040087623A1 (en) 2001-02-02 2004-05-06 Gellibert Francoise Jeanne Pyrazole derivatives against tgf overexpression
GB0102665D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
EP1363904A1 (en) 2001-02-02 2003-11-26 Glaxo Group Limited Pyrazoles as tgf inhibitors
JP2004532234A (ja) 2001-04-27 2004-10-21 バーテックス　ファーマシューティカルズ　インコーポレイテッド トリアゾール由来キナーゼインヒビターおよびその使用
US6727364B2 (en) 2001-04-30 2004-04-27 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6787555B2 (en) 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
GB0127433D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
DE60222465T2 (de) 2001-12-11 2008-06-05 Smithkline Beecham Corp. Pyrazolopyridin-derivate als antiherpesmittel
US20040038856A1 (en) 2002-05-17 2004-02-26 Sarvajit Chakravarty Treatment of fibroproliferative disorders using TGF-beta inhibitors
WO2004026871A1 (en) * 2002-09-17 2004-04-01 Eli Lilly And Company Novel pyrazolopyridine derivatves as pharmaceutical agents
DE60328028D1 (de) 2002-09-18 2009-07-30 Pfizer Prod Inc Imidazolverbindungen als inhibitoren des transformierenden wachstumsfaktors (twf)
BR0314383A (pt) 2002-09-18 2005-07-19 Pfizer Prod Inc Compostos de oxazol e tiazol como inibidores do fator de crescimento transformante(tgf)
WO2004060362A2 (en) 2003-01-02 2004-07-22 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-β
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
CA2537841A1 (en) 2003-09-06 2005-03-24 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters

Also Published As

Publication number Publication date
CA2497970A1 (en) 2004-03-18
NO20051503L (no) 2005-03-21
CN1694698A (zh) 2005-11-09
WO2004022054A1 (en) 2004-03-18
RS20050200A (en) 2007-08-03
GEP20074125B (en) 2007-06-11
AR041207A1 (es) 2005-05-11
EA200500450A1 (ru) 2005-08-25
PL375699A1 (en) 2005-12-12
BR0314053A (pt) 2005-07-19
UA80295C2 (en) 2007-09-10
AU2003268447A1 (en) 2004-03-29
US20060106033A1 (en) 2006-05-18
AU2003268447B2 (en) 2008-07-24
JP2006502165A (ja) 2006-01-19
KR20050057235A (ko) 2005-06-16
EP1551398A1 (en) 2005-07-13
EP1551398A4 (en) 2006-06-07
MXPA05002443A (es) 2005-09-30
EA009441B1 (ru) 2007-12-28
NO20051503D0 (no) 2005-03-21
US7691865B2 (en) 2010-04-06
NZ539069A (en) 2007-03-30
IS7725A (is) 2005-03-04
ZA200501856B (en) 2006-04-26

Similar Documents

Publication Publication Date Title
IS7726A (is) Pyrazólólpyridín og aðferðir til þess að búa þau til og nota
DK1465615T3 (da) Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf
NO20040640L (no) Anordning og fremgangsmate
NO20032220D0 (no) Löfteverktöy II og fremgangsmåte for anvendelse av samme
IS8204A (is) Tæki og aðferð til að hluta niður
DK1606283T3 (da) P38-inhibitorer og fremgangsmåder til anvendelse deraf
IS8037A (is) P38-hindrar og aðferðir til notkunar þeirra
IS8146A (is) Setnar 3-alkýl og 3-alkenýl asetidín afleiður
IS7701A (is) Arípíprazól samsett lyfjaform og aðferð
NO20053817D0 (no) Preparater og fremgangsmater for antiviral kombinasjonsterapi.
NO20031776D0 (no) Null-boringskomplettering og produksjonssystem
IS8153A (is) Ónæmisbælandi efnasambönd og efnablöndur
DK1527067T3 (da) 4-Trifluormethylpyrazolylsubstituerede pyridiner og pyrimidiner
DK1511734T3 (da) Forbindelser, præparater og fremgangsmåder
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
NO20053593D0 (no) Arylalkylkarbamat-derivater, fremgangsmate og anvendelse derav i terapi
IS8489A (is) Umritunarstillar og aðferðir þeirra
DK1426784T3 (da) Indretning og fremgangsmåde til positionsbestemmelse
NO20055778D0 (no) Folgesystem og assosiert fremgangsmate
DK1359458T3 (da) Brillestel og hængselsenhed til anvendelse deri
NO20044012D0 (no) Fremgangsmate og et system
IS7572A (is) Aðferð og efni til lækninga
DK1667693T3 (da) Præparater og fremgangsmåder til anvendelse af lamellare bodies til terapeutiske formål
NO20044848D0 (no) Anordning og fremgangsmate
DK1662867T3 (da) Insekticid-forbindelser og fremgangsmåder til valg deraf